Phenogen Sciences, Inc., a US division of Australia-based Genetic Technologies Limited, was established in 2010 as a global expansion strategy of the company’s oncology and cancer management diagnostics business. As a pioneer in personalized healthcare, Phenogen Sciences offers novel predictive testing and risk assessment tools that help physicians proactively manage the health of their patients. Phenogen’s lead product, BREVAGenplus™, now geneType, was the first clinically validated predictive risk test that combines genetic and clinical data to categorize a woman’s personal risk of developing breast cancer. Phenogen's risk assessment product line, geneType, has expanded beyond breast cancer. We've utilized our expertise in integrated risk model development to build assessments in a variety of other diseases including other cancer types, cardiovascular, metabolic and infectious disease. Our parent company, Genetic Technologies Limited (NASDAQ: GENE) is based in Melbourne, Australia. For more than 20 years, the company has provided laboratory services in molecular diagnostics and was an early pioneer in recognizing important new applications for ‘non-coding’ DNA (Deoxyribonucleic Acid). The company has since been granted patents in 24 countries around the world.